广东省广州市天河区珠江新城华夏路 10 号富力中心 23 楼整层及 31 楼 01、04 单元 邮编：510623 23/F, Units 01 & 04 of 31/F, R&F Center, 10 Huaxia Road, Zhujiang New Town, Tianhe District Guangzhou, Guangdong 510623, P. R. China 电话/Tel : +86 20 2826 1688 传真/Fax : +86 20 2826 1666 www.zhonglun.com 北京市中伦（广州）律师事务所 关于广州若羽臣科技股份有限公司 2024 年年度股东大会的法律意见书 致：广州若羽臣科技股份有限公司 北京市中伦（广州）律师事务所（以下简称"本所"）受广州若羽臣科技股份 有限公司（以下简称"公司"）委托，指派本所律师邵芳、刘杰（以下简称"本所 律师"）出席公司 2024 年年度股东大会（以下简称"本次股东大会"）。本所律 师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司股东 会规则》等有关法律、法规、规范性文件及《广州若羽臣科技股份有限公司章程》 ...

证券代码：003010 证券简称：若羽臣 公告编号：2025-045 广州若羽臣科技股份有限公司 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 广州若羽臣科技股份有限公司（以下简称"公司""若羽臣"）于2025年2 月26日披露了《关于持股5%以上股东减持股份预披露公告》 （公告编号：2025-015）， 朗姿股份有限公司（以下简称"朗姿股份"）计划合计减持若羽臣股份数量不超 过4,768,071股，不超过若羽臣总股本的3%。其中，通过集中竞价方式减持不超 过1,589,357股，不超过若羽臣总股本的1%，且在任意连续90个自然日内减持股 份的总数不超过若羽臣总股本的1%；通过大宗交易方式减持不超过3,178,714股， 不超过若羽臣总股本的2%，且任意连续90个自然日内减持股份的总数不超过若羽 臣总股本的2%。（总股本以公司当前总股本164,030,506股剔除公司截至本公告 披露日已披露回购结果的2024年第三期股份回购和2024年第四期股份回购的回 购专用证券账户持有的5,094,800股后的股份数量158,935,706 股为计算依据， 下同。） 公司于2025年3月22日、20 ...

广州若羽臣科技股份有限公司（以下简称"公司""若羽臣"）于2025年2 月26日披露了《关于持股5%以上股东减持股份预披露公告》（公告编号：2025-015）， 朗姿股份有限公司（以下简称"朗姿股份"）计划合计减持若羽臣股份数量不超 过4,768,071股，不超过若羽臣总股本的3%。其中，通过集中竞价方式减持不超 过1,589,357股，不超过若羽臣总股本的1%，且在任意连续90个自然日内减持股 份的总数不超过若羽臣总股本的1%；通过大宗交易方式减持不超过3,178,714股， 不超过若羽臣总股本的2%，且任意连续90个自然日内减持股份的总数不超过若羽 臣总股本的2%。（总股本以公司当前总股本164,030,506股剔除公司截至本公告 披露日已披露回购结果的2024年第三期股份回购和2024年第四期股份回购的回 购专用证券账户持有的5,094,800股后的股份数量158,935,706 股为计算依据， 下同。） 公司于2025年3月22日、2025年5月14日和2025年5月16日分别披露了《关于 持股5%以上股东权益变动后持股比例触及5%整数倍的提示性公告》（公告编号： 2025-021）、《简式权益变动报 ...

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Viewpoints - The company has launched a significant new product, Ruby Oil, which is expected to expand its health supplement business [2] - The self-owned brands, Zhanjia and Feicui, are driving growth with Zhanjia projected to achieve a revenue of 501 million yuan in 2024, a year-on-year increase of 90.28% [2] - The company's profitability is expected to improve due to the growth of its self-owned brands, with gross margins and net profit margins increasing in 2024 [3] - The brand management business is showing strong growth, with revenue expected to reach 501 million yuan in 2024, a year-on-year increase of 212.24% [3] - The company has adjusted its net profit forecasts for 2025 and 2026 upwards due to better-than-expected growth in self-owned brands, with a new forecast for 2027 net profit of 300 million yuan [4] Financial Projections - Total revenue is projected to grow from 1,366 million yuan in 2023 to 4,762 million yuan in 2027, with a compound annual growth rate (CAGR) of approximately 31.04% [1] - The net profit attributable to the parent company is expected to increase from 54.29 million yuan in 2023 to 302.92 million yuan in 2027, reflecting a CAGR of approximately 30.37% [1] - The earnings per share (EPS) is forecasted to rise from 0.33 yuan in 2023 to 1.85 yuan in 2027 [1]

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Insights - The company has launched a significant new product, Ruby Oil, which is expected to expand its health supplement business [2] - The self-owned brands, Zhanjia and Feicui, are driving growth with Zhanjia projected to achieve a revenue of 5.01 billion yuan in 2024, a year-on-year increase of 90.28% [2] - The company's profitability is expected to improve due to the growth of its self-owned brands, with gross margins and net profit margins increasing in 2024 [3] - The brand management business is showing strong growth, with revenue expected to reach 5.01 billion yuan in 2024, a year-on-year increase of 212.24% [3] - The company has adjusted its net profit forecasts for 2025 and 2026 upwards due to better-than-expected growth in self-owned brands [4] Financial Projections - Total revenue is projected to grow from 1.37 billion yuan in 2023 to 4.76 billion yuan in 2027, with a compound annual growth rate (CAGR) of 31.04% [1] - Net profit attributable to the parent company is expected to increase from 54.29 million yuan in 2023 to 302.92 million yuan in 2027, reflecting a CAGR of 30.37% [1] - The earnings per share (EPS) is forecasted to rise from 0.33 yuan in 2023 to 1.85 yuan in 2027 [1]

Group 1 - The core viewpoint of the articles highlights the successful launch of new products by the companies, specifically the introduction of the "Ruby Oil" by Feicui, which is a high-end fish oil designed for women, featuring unique ingredients that enhance absorption and provide various health benefits [1] - Feicui's new brand is expected to leverage the unique Ruby Oil ingredient, which has a differentiated structure, leading to a high certainty of success in the health supplement market [1] - The company has established a strong operational experience in health supplements, which, combined with the exclusive new ingredient, positions the new brand for high certainty in its market performance [1] Group 2 - Zhenjia has experienced significant growth in sales through dual channels, with a 547% year-on-year increase in sales on Douyin as of May 18, indicating a strong market presence and potential for further acceleration during promotional events [1] - On Tmall, Zhenjia ranked among the top 10 in the home cleaning category during the 618 pre-sale event, showcasing a 7-position improvement compared to the previous year, reflecting its growing popularity [1] - The company is positioned to capitalize on the consumer upgrade trend in the home cleaning sector, with a focus on high-end fragrance products that meet evolving consumer demands [1][2] Group 3 - The investment recommendation emphasizes the differentiated positioning of Zhenjia and Feicui in the high-end fragrance home cleaning and oral beauty markets, suggesting a strong growth trajectory driven by new consumer scenarios and multiple product offerings [2] - The unique Ruby Oil is anticipated to be a significant growth driver for Feicui, reinforcing the high certainty of success in the new brand development [2] - The companies are expected to focus on core female demographics and explore niche market demands, aiming to create a "small but beautiful" brand matrix that aligns with consumer trends [2]

Summary of Conference Call Records Industry Overview: Health Supplements - The health supplement industry is experiencing structural growth, with a compound annual growth rate (CAGR) of 5% from 2017 to 2022, indicating mid-to-low growth but emerging opportunities under new consumption trends [1][2] - The market size for health supplements is approximately over 1 trillion yuan, with significant potential for growth as new consumption companies enter the sector [2] Key Companies and Their Performance Xianle Health - Xianle Health has successfully transformed from an OEM to a new consumption company, achieving profitability and valuation improvement since 2022 by divesting loss-making businesses [1][5][36] Yanjichu - Yanjichu, a leading OEM in bird's nest products, has a competitive edge with 2,000 clients and 70 patents. If it can penetrate the consumer market, its valuation could rise significantly from below 15 times to over 20 times [1][11][12] Yanjinpuzi - Yanjinpuzi has shown strong market performance since 2021, benefiting from bulk retail channels. Despite short-term profit margin declines, long-term growth potential remains promising [1][3][4] HH International Holdings - HH International focuses on adult health products and is benefiting from online transformation. The company is upgrading its brand matrix and reducing debt to optimize interest expenses [3][29] Tongchen Beijian - Tongchen Beijian has become a market leader in health supplements since 2019, with a stable market share of nearly 10%. The company is focusing on new product launches and online sales channels [26][35] Baihe Health - Baihe Health is expanding into new channels, particularly membership supermarkets, which are expected to double its scale this year [37] Market Trends and Dynamics - The global health supplement market is growing steadily, with China's growth rate surpassing the global average, driven by aging populations and new consumption trends [3][20][22] - The online transformation of health brands is accelerating, with e-commerce channels gaining a significant share of the market [25][27] - The health supplement industry is characterized by high gross margins, primarily due to strong brand attributes and a fragmented supply chain [14][15][16] Investment Opportunities and Risks - The health supplement sector presents substantial investment opportunities, akin to blue-chip stocks from a few years ago, with new brands needing to embrace new consumption paths [9][10] - The industry is witnessing a shift towards light asset models, with increasing product homogeneity and a fragmented brand landscape [28] - The aging population in China is a fundamental driver for the health supplement market, as older consumers have a consistent demand for health products [23][24] Conclusion - The health supplement industry is poised for growth, with several companies demonstrating strong performance and potential for further expansion. Investors are encouraged to consider the emerging opportunities within this sector, particularly as new consumption trends reshape the market landscape [1][9][24]

Group 1 - The concept of ergothioneine has gained significant attention in the A-share market, with stocks related to this concept experiencing strong price increases [2][3] - Key stocks in the ergothioneine sector include Tuoxin Pharmaceutical and Chuaning Biological, both of which reached their daily limit up, while other companies like Bawei Co., Xianle Health, and Huaxi Biological also saw gains [2][3] - The chairman of Kelun Pharmaceutical, Liu Gexin, has endorsed the company's anti-aging product "ergothioneine capsules," claiming to have used the product for three years, which has contributed to the product's popularity [2][3] Group 2 - Kelun Pharmaceutical reported a revenue of 4.39 billion yuan in Q1, a year-on-year decline of 29.42%, with a net profit of 584 million yuan, down 43.07% [2][4] - The decline in revenue and profit is attributed to high base effects from the previous year and the impact of centralized procurement on the infusion business [2][4] - The company aims to establish a new subsidiary, Kelun Yongnian, to focus on the sales of ergothioneine products, indicating a strategic shift towards the health industry [3][4] Group 3 - There are 14 stocks in the A-share market related to ergothioneine, with Huadong Medicine, Kelun Pharmaceutical, and Chuaning Biological having the largest market capitalizations [4] - The average stock price increase for ergothioneine-related stocks this year is 19.16%, with Ruoyuchen leading with a 104.62% increase [4] - Half of the ergothioneine concept stocks reported positive net profits in Q1, with companies like Changshan Pharmaceutical turning losses into profits [4] Group 4 - There was a significant net inflow of capital into ergothioneine concept stocks today, with Chuaning Biological, Jindawei, and Kelun Pharmaceutical seeing the highest net inflows of 563 million yuan, 153 million yuan, and 129 million yuan respectively [5]

Group 1 - The pet economy concept rose by 1.98%, ranking third among concept sectors, with 54 stocks increasing in value, including major gainers like Meino Biological and Jieya Co., which hit the 20% limit up [1][2] - Notable stocks with significant increases include Xianle Health, Huisheng Biological, and Yiyuan Magic Yam, which rose by 13.41%, 10.50%, and 9.10% respectively [1] - The leading decliners in the sector were Zhiou Technology, Qingmu Technology, and Yingstone Network, which fell by 4.64%, 4.42%, and 2.73% respectively [1] Group 2 - The pet economy sector saw a net inflow of 236 million yuan, with 48 stocks receiving net inflows, and 7 stocks attracting over 30 million yuan each [2] - The top stock for net inflow was Yong'an Pharmaceutical, with a net inflow of 68.36 million yuan, followed by Jieya Co., Ruoyuchen, and Meino Biological with net inflows of 48.24 million yuan, 46.14 million yuan, and 45.47 million yuan respectively [2][3] Group 3 - In terms of net inflow ratios, Jieya Co., Jiabiyou, and Meino Biological led with net inflow rates of 27.98%, 13.31%, and 11.04% respectively [3] - The pet economy sector's inflow ranking included stocks like Yong'an Pharmaceutical, Jieya Co., Ruoyuchen, and Meino Biological, all showing strong performance in terms of trading volume and turnover rates [3][4]

本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 广州若羽臣科技股份有限公司（以下简称"公司""若羽臣"）于2025年2 月26日披露了《关于持股5%以上股东减持股份预披露公告》（公告编号：2025-015）， 朗姿股份有限公司（以下简称"朗姿股份"）计划合计减持若羽臣股份数量不超 过4,768,071股，不超过若羽臣总股本的3%。其中，通过集中竞价方式减持不超 过1,589,357股，不超过若羽臣总股本的1%，且在任意连续90个自然日内减持股 份的总数不超过若羽臣总股本的1%；通过大宗交易方式减持不超过3,178,714股， 不超过若羽臣总股本的2%，且任意连续90个自然日内减持股份的总数不超过若羽 臣总股本的2%。（总股本以公司当前总股本164,030,506股剔除公司截至本公告 披露日已披露回购结果的2024年第三期股份回购和2024年第四期股份回购的回 购专用证券账户持有的5,094,800股后的股份数量158,935,706 股为计算依据， 下同。） 2025年3月22日，公司于巨潮资讯网（http://www.cninfo.com.cn）披露了 《关于持股5%以上股东权益变动后持 ...